Immunopathology of secondary‐progressive multiple sclerosis

Twenty‐three plaques obtained at early autopsy from 2 patients with secondary‐progressive multiple sclerosis were examined immunohistochemically for microglia/macrophages, and for immunoglobulins and components of activated complement. Most of the lesions examined in both cases exhibited evidence of low‐grade active demyelination of an unusual type (frustrated phagocytosis) in periplaque white matter. This included linear groups of microglia engaging short segments of disrupted myelin that were associated with deposits of C3d, an opsonin formed during complement activation. Similar microglia/C3d/myelin profiles were not observed in newly forming lesions in cases of acute multiple sclerosis or other central white matter diseases. As C3d coupling is known to increase the immunogenicity of potential antigens enormously, present findings point to disrupted myelin close to plaques as a possible source of the putative multiple sclerosis antigen. Ongoing myelin destruction found in a high proportion of old, established plaques was surprising. It suggests that slowly expanding lesions (progressive plaques), in which ongoing myelin breakdown occurs in the absence of florid perivascular cell cuffing or other histological signs of acute inflammation, contribute to disease progression in cases of secondary‐progressive multiple sclerosis.

[1]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[2]  B. Scheithauer,et al.  A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. , 1999, Brain : a journal of neurology.

[3]  V. Stevenson,et al.  Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis , 1999, Multiple sclerosis.

[4]  S. Hauser,et al.  Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case for antigen‐specific antibody mediation , 1999, Annals of neurology.

[5]  Bruce D. Trapp,et al.  Axonal pathology in myelin disorders , 1999, Journal of neurocytology.

[6]  P. Sminia,et al.  Expression of transforming growth factor (TGF)-beta1, -beta2, and -beta3 isoforms and TGF-beta type I and type II receptors in multiple sclerosis lesions and human adult astrocyte cultures. , 1999, Journal of neuropathology and experimental neurology.

[7]  R. Rudick,et al.  Neurodegeneration in Multiple Sclerosis: Relationship to Neurological Disability , 1999 .

[8]  P M Matthews,et al.  Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.

[9]  M. Filippi,et al.  Newer magnetic resonance techniques and disease activity in multiple sclerosis: new concepts and new concerns , 1998, Multiple sclerosis.

[10]  H. Lassmann,et al.  Multiple sclerosis: In situ evidence for antibody‐ and complement‐mediated demyelination , 1998, Annals of neurology.

[11]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[12]  M. Esiri,et al.  The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. , 1997, Brain : a journal of neurology.

[13]  R. Hohlfeld,et al.  Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. , 1997, Brain : a journal of neurology.

[14]  V. Perry,et al.  Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.

[15]  W. Russell Molecular biology of multiple sclerosis , 1997 .

[16]  J. Newcombe,et al.  The Expression of Tissue‐type Plasminogen Activator, Matrix Metalloproteases and Endogenous Inhibitors in the Central Nervous System in Multiple Sclerosis: Comparison of Stages in Lesion Evolution , 1996, Journal of neuropathology and experimental neurology.

[17]  A J Thompson,et al.  Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. , 1996, Brain : a journal of neurology.

[18]  L. Laan,et al.  Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-α and nitric oxide , 1996, Journal of Neuroimmunology.

[19]  B. Trapp,et al.  Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. , 1996, Journal of neuropathology and experimental neurology.

[20]  M. Cuzner,et al.  Biochemistry of Demyelination , 1996, Brain pathology.

[21]  P M Matthews,et al.  Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. , 1996, Brain : a journal of neurology.

[22]  J Newcombe,et al.  Microglia‐derived macrophages in early multiple sclerosis plaques , 1996, Neuropathology and applied neurobiology.

[23]  R. Locksley,et al.  The Instructive Role of Innate Immunity in the Acquired Immune Response , 1996, Science.

[24]  R. Sobel,et al.  Matrix Metalloproteinases in the Normal Human Central Nervous System, Microglial Nodules, and Multiple Sclerosis Lesions , 1996, Journal of neuropathology and experimental neurology.

[25]  P. Mcgeer,et al.  Neurofibrillary tangles of Guam parkinson-dementia are associated with reactive microglia and complement proteins , 1996, Brain Research.

[26]  Hans Lassmann,et al.  Monocyte/macrophage differentiation in early multiple sclerosis lesions , 1995, Annals of neurology.

[27]  R. Mrak,et al.  Interleukin‐1 Expression in Different Plaque Types in Alzheimer's Disease: Significance in Plaque Evalution , 1995, Journal of neuropathology and experimental neurology.

[28]  P. Mattsson,et al.  Evidence for activation of the terminal pathway of complement and upregulation of sulfated glycoprotein (SGP)-2 in the hypoglossal nucleus following peripheral nerve injury. , 1995, Molecular and chemical neuropathology.

[29]  Jack Antel,et al.  Phenotypic Differences between Human Monocytes/Macrophages and Microglial Cells Studied In Situ and In Vitro , 1994, Journal of neuropathology and experimental neurology.

[30]  A J Thompson,et al.  A comparison of the pathology of primary and secondary progressive multiple sclerosis. , 1994, Brain : a journal of neurology.

[31]  K. Williams,et al.  Activation of adult human derived microglia by myelin phagocytosis in vitro , 1994, Journal of neuroscience research.

[32]  P. Matthews,et al.  Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis , 1994, Annals of neurology.

[33]  J. Antel,et al.  Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG , 1994, Journal of the Neurological Sciences.

[34]  A. Olivier,et al.  Fc Receptors for IgG on Cultured Human Microglia Mediate Cytotoxicity and Phagocytosis of Antibody-coated Targets , 1994, Journal of neuropathology and experimental neurology.

[35]  M. Cuzner,et al.  Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. , 1993, Cytokine.

[36]  G. Opdenakker,et al.  Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein , 1993, Journal of neuroscience research.

[37]  H. Rabb,et al.  Cytoplasmic tails of human complement receptor type 3 (CR3, CD11b/ CD18) regulate ligand avidity and the internalization of occupied receptors. , 1993, Journal of immunology.

[38]  W. Tourtellotte,et al.  On classification of post-mortem multiple sclerosis plaques for neuroscientists , 1993, Journal of Neuroimmunology.

[39]  J. Newcombe,et al.  Characterization and distribution of phagocytic macrophages in multiple sclerosis plaques , 1993, Neuropathology and applied neurobiology.

[40]  C. Raine,et al.  Multiple Sclerosis: Remyelination in Acute Lesions , 1993, Journal of neuropathology and experimental neurology.

[41]  E. Cho,et al.  Multiple sclerosis: Remyelination of nascent lesions: Remyelination of nascent lesions , 1993 .

[42]  D. Walker,et al.  Microglia in degenerative neurological disease , 1993, Glia.

[43]  E. Cho,et al.  Multiple sclerosis: remyelination of nascent lesions. , 1993, Annals of neurology.

[44]  P. Mcgeer,et al.  Complement activation by beta-amyloid in Alzheimer disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[45]  B E Kendall,et al.  The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. , 1991, Brain : a journal of neurology.

[46]  W. Mcdonald,et al.  The longstanding MS lesion. A quantitative MRI and electron microscopic study. , 1991, Brain : a journal of neurology.

[47]  H. Link,et al.  Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls , 1991, Journal of Neuroimmunology.

[48]  Sunhee C. Lee,et al.  Multiple Sclerosis: A Role for Astroglia in Active Demyelination Suggested by Class II MHC Expression and Ultrastructural Study , 1990, Journal of neuropathology and experimental neurology.

[49]  J. Prineas,et al.  Sera from MS patients and normal controls opsonize myelin , 1990, Neuroscience Letters.

[50]  J. Benjamins,et al.  Opsonization of normal myelin by anti-myelin antibodies and normal serum , 1989, Journal of Neuroimmunology.

[51]  L. Scheinberg,et al.  On the immunopathology of plaque development and repair in multiple sclerosis , 1988, Journal of Neuroimmunology.

[52]  H. Lassmann,et al.  Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. , 1988, The American journal of pathology.

[53]  E. G. Gray,et al.  Alzheimer’s disease: coated vesicles, coated pits and the amyloid-related cell , 1988, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[54]  C. Brosnan,et al.  Complement potentiates the degradation of myelin proteins by plasmin: Implications for a mechanism of inflammatory demyelination , 1986, Brain Research.

[55]  M. Shin,et al.  Isolation of Membrane Attack Complex of Complement from Myelin Membranes Treated with Serum Complement , 1984, Journal of neurochemistry.

[56]  L. Epstein,et al.  Attachment of myelin to coated pits on macrophages in experimental allergic encephalomyelitis , 1983, Journal of the Neurological Sciences.

[57]  Dr. med. Hans Lassmann Comparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis , 1983, Schriftenreihe Neurologie / Neurology Series.

[58]  M. Shin,et al.  Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Mussini,et al.  [Immunology of multiple sclerosis]. , 1982, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.

[60]  L. Scheinberg,et al.  Multiple sclerosis. Oligodendrocyte survival and proliferation in an active established lesion. , 1981, Laboratory investigation; a journal of technical methods and pathology.

[61]  H. Fleury,et al.  FURTHER ULTRASTRUCTURAL OBSERVATIONS OF VIRUS MORPHOGENESIS AND MYELIN PATHOLOGY IN JHM VIRUS ENCEPHALOMYELITIS , 1980, Neuropathology and applied neurobiology.

[62]  H. Nyland,et al.  Fc receptors of microglial lipophages in multiple sclerosis. , 1980, The New England journal of medicine.

[63]  M. Cuzner,et al.  Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis , 1978, Annals of neurology.

[64]  J. Prineas,et al.  The fine structure of chronically active multiple sclerosis plaques , 1978, Neurology.

[65]  J. Aarli,et al.  Binding of normal human IgG to myelin sheaths, glia and neurons. , 1975, Immunology.